CLCM
TGTX icon

Crawford Lake Capital Management’s TG Therapeutics TGTX Stock Holding History

Crawford Lake Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-80,000
Closed -$864K – 142
2017
Q1 		$864K Buy
+80,000
New +$574K 0.34% 55

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Crawford Lake Capital Management's TGTX Position: Q2 2021 in Review

Crawford Lake Capital Management sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 21,963 shares — an estimated $1.06M sold.

Crawford Lake Capital Management first reported a position in TGTX in Q4 2020 and held it in 2 quarters. The position peaked at $1.78M in Q4 2020. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

  • Crawford Lake Capital Management reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Crawford Lake Capital Management sold 21,963 TG Therapeutics shares in Q2 2021, an estimated $1.06M.
  • Crawford Lake Capital Management first reported a position in TG Therapeutics in Q4 2020 and held it in 2 quarters.
  • Crawford Lake Capital Management's TG Therapeutics position peaked at $1.78M in Q4 2020.
  • 237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on Crawford Lake Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.